Shirai Katsuyuki, Endo Masashi, Aoki Shuri, Kishi Noriko, Fukuda Yukiko, Nonaka Tetsuo, Ishikawa Hitoshi
Department of Radiology, Jichi Medical University Hospital, Shimotsuke 329-0498, Japan.
Department of Radiation Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Cancers (Basel). 2025 Aug 4;17(15):2569. doi: 10.3390/cancers17152569.
Systemic chemotherapy is a standard treatment for patients with stage IV cancer with distant metastases, and there is little evidence of the effectiveness of local treatments for distant metastatic lesions. However, in recent years, randomized phase II trials targeting oligometastases in lung cancer and solid tumors have reported that local therapy combined with systemic chemotherapy improves clinical outcomes. We reviewed previous clinical trials and demonstrated the efficacy of radiotherapy for oligometastatic disease. Stereotactic body radiotherapy (SBRT) is a promising treatment that achieves high local control rates for oligometastatic disease. Although SBRT generally does not cause severe adverse events, the safety of SBRT combined with systemic chemotherapy needs to be carefully considered. We discussed the efficacy and safety of SBRT and summarized the details of SBRT methods and techniques for each metastatic site. Further research and clinical trials are warranted to improve the efficacy of SBRT combined with systemic chemotherapy for oligometastatic non-small cell lung cancer (NSCLC).
全身化疗是IV期伴有远处转移癌症患者的标准治疗方法,几乎没有证据表明局部治疗对远处转移病灶有效。然而,近年来,针对肺癌和实体瘤寡转移的随机II期试验报告称,局部治疗联合全身化疗可改善临床结局。我们回顾了既往临床试验并证明了放疗对寡转移疾病的疗效。立体定向体部放疗(SBRT)是一种有前景的治疗方法,可实现对寡转移疾病的高局部控制率。虽然SBRT一般不会引起严重不良事件,但SBRT联合全身化疗的安全性仍需仔细考虑。我们讨论了SBRT的疗效和安全性,并总结了每个转移部位SBRT方法和技术的细节。有必要进行进一步的研究和临床试验,以提高SBRT联合全身化疗治疗寡转移非小细胞肺癌(NSCLC)的疗效。